araag2/HINT huggingface dataset:
Clinical trial NCT01478308 (phase 2, status: withdrawn)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: metformin hydrochloride, docetaxel, prednisone
SMILES: CN(C)C(=N)NC(N)=N, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C
Reason stopped: 
    no accrual in initial period, pi decided to close study.
  
Eligibility criteria:

        Inclusion Criteria:

          -  All patients, 18 of age or older, with hormone refractory prostate cancer are
             eligible.

          -  Patients must have a life expectancy of at least 12 weeks.

          -  Patients must have a Zubrod performance status of 0-2.

          -  Patients must sign an informed consent.

          -  Patients should have adequate bone marrow function defined by an absolute peripheral
             granulocyte count of > 1,500 or cells/mm3 and platelet count >100,000/mm3 and absence
             of a regular red blood cell transfusion requirement.

          -  Patients should have adequate hepatic function with a total bilirubin < 2 mg/dl and
             SGOT or SGPT < two times the upper limit of normal, and adequate renal function as
             defined by a serum creatinine < 1.5 x upper limit of normal.

          -  Patients must have pathologically confirmed prostate cancer with PSA increasing
             despite androgen deprivation therapy.

          -  Diabetic patients on therapy with Metformin are eligible provided that their Metformin
             dose is at least 850mg twice daily.

        Exclusion Criteria:

          -  Patients with symptomatic brain metastases are excluded from this study.

          -  Patients on insulin are not eligible.

          -  Patients may receive no other concurrent chemotherapy or radiation therapy during this
             trial.

          -  Patients with severe medical problems such as uncontrolled diabetes mellitus,
             cardiovascular disease, and congestive heart failure defined as New York Heart
             Association Class III or IV, hepatic dysfunction, or active infections are not
             eligible for this trial.
Clinical trial NCT00470067 (phase 2, status: terminated)
Conditions: endometrial cancer
ICD codes: N85.00, N85.01, N85.02, N99.85
Drugs: carboplatin, pegylated liposomal doxorubicin hydrochloride
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
Reason stopped: 
    due to low accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed primary endometrial carcinoma meeting 1 of the following
             criteria:

               -  Stage III or IV disease according to FIGO staging criteria

               -  Recurrent disease that is considered incurable

          -  Measurable disease

               -  A lesion within a previously irradiated field is acceptable as measurable disease
                  only if there has been clear progression since completion of radiotherapy

        PATIENT CHARACTERISTICS:

          -  GOG performance status 0-2

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 9 g/dL

          -  Creatinine < 2.5 mg/dL OR creatinine clearance ≥ 60 mL/min

          -  ALT and AST ≤ 1.5 times upper limit of normal (ULN) (3 times ULN in the presence of
             liver metastases)

          -  Alkaline phosphatase ≤ 1.5 times ULN (3 times ULN in the presence of liver metastases)

          -  Total bilirubin ≤ 1.5 times ULN (3 times ULN in the presence of liver metastases)

          -  Not pregnant or nursing

          -  Left ventricular ejection fraction (LVEF) ≥ 50% by MUGA scan or ECHO

          -  No history of severe hypersensitivity reaction to doxorubicin hydrochloride liposome

          -  No other invasive malignancy (i.e., breast cancer) within the past 5 years except
             nonmelanoma skin cancer

          -  No cardiac disease, including any of the following:

               -  Myocardial infarction within the past 6 months

               -  NYHA class II-IV heart failure

               -  Uncontrolled angina

               -  Severe uncontrolled ventricular arrhythmias

               -  Clinically significant pericardial disease

               -  Acute ischemic or active conduction system abnormalities by ECHO

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy

          -  No prior cancer therapy that would contraindicate study treatment

          -  No concurrent investigational agents
Clinical trial NCT01618968 (phase 2, status: completed)
Conditions: rheumatoid arthritis (ra)
ICD codes: M05.9, M06.08, M06.00, M06.011, M06.012, M06.019, M06.021
Drugs: mtx
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female patients ≥18 years of age, diagnosed with Rheumatoid Arthritis

        Exclusion Criteria:

          -  Pregnant females

          -  Any other clinically significant disease or disorder which, in the opinion of the
             investigator might put the subject at risk
Clinical trial NCT00504452 (phase 2, status: terminated)
Conditions: hiv infections
ICD codes: Z21
Drugs: kp-1461
SMILES: CCCCCCCOC(=O)NC1=NC(=O)N(CN1)[C@H]1C[C@H](O)[C@@H](CO)O1
Reason stopped: 
    corroboration of supporting in vitro data

    - data successfully corroborated 2009
  
Eligibility criteria:

        Inclusion Criteria:

          -  Asymptomatic HIV-1-infected individuals who are treatment-experienced and who have not
             been on ART for at least 16 weeks.

          -  Have documented prior non-suppressive ART including at least 1 NRTI, 1 NNRTI and 2
             PIs; or have documented prior ART resistance to at least 1 NRTI, 1 NNRTI and 1 PI; AND
             in the opinion of the investigator, have few, if any, effective treatment options
             available.

          -  Have >2,500 copies/mL of HIV-1 RNA at screening.

          -  Have a stable CD4 cell count while off ART and >250 cells/mL at screening.

          -  Have no clinically significant findings on screening evaluations.

        Exclusion Criteria:

          -  Have a current or recent opportunistic infection that, in the opinion of the
             investigator, is not being controlled by medication.

          -  Have any condition that, in the opinion of the investigator, could compromise subject
             safety or adherence to the protocol.

          -  Have a documented positive test for hepatitis B surface antigen, or have received any
             antiviral therapy for hepatitis C <6 weeks prior to study drug administration.
Clinical trial NCT00633464 (phase 2, status: completed)
Conditions: triple negative locally advanced non-resectable breast cancer, metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: ixabepilone, ixabepilone + cetuximab
SMILES: [H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\C)=C\C1=CSC(C)=N1, [H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\C)=C\C1=CSC(C)=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Female subjects with triple negative (ER, PR, and HER2 negative) locally advanced
             non-resectable and/or metastatic breast cancer

          -  Prior adjuvant or neoadjuvant anthracycline-based chemotherapy

        Exclusion Criteria:

          -  Tumors that are fluorescence in situ hybridization test (FISH) positive or
             immunohistochemistry (IHC) 3+

          -  Neuropathy > Grade 1

          -  Prior systemic therapy for metastatic disease
Clinical trial NCT00515229 (phase 2, status: completed)
Conditions: cystic fibrosis, infection, pseudomonas aeruginosa
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4, K94.02, K94.12, K94.22, K94.32, N99.511, A02.9, A31.0, B96.5
Drugs: amitriptyline
SMILES: CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          1. Cystic Fibrosis is proved

          2. The patient are older than 18 years (<50 years)

          3. No sec discrimination

          4. The patient is pulmonal colonized with bacteria

          5. Signs of pulmonary exacerbation are not present

          6. A full course of therapy is possible without any restrictions

          7. Lung function measurement is possible

        Exclusion Criteria:

          1. Poor metabolizer for amitriptyline (CYP2D6 genotyping)

          2. Glaucoma, seizures, heart insufficiency or depression is present

          3. Signs of acute pulmonary illness (bronchial or tracheal stenosis, tuberculosis, thorax
             trauma, acute pneumonia, pneumothorax, bronchial haemorrhage, ARDS) are present

          4. intravenous antibiotic treatment was necessary in the last 4 weeks

          5. Involvement of the patient in another study

          6. Pregnancy
Clinical trial NCT01357980 (phase 2, status: completed)
Conditions: detrusor muscle hyperactivity
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject, family member or care giver was willing and able to perform clean
             intermittent catheterisation (CIC) for the duration of the study

          -  Inadequate response or refractory to anticholinergic medication

          -  Botulinum Toxin naive for intradetrusor injections and with no previous treatment with
             Botulinum Toxin of any type, within 3 months prior to study entry for any other
             condition

          -  Have a minimum of 2 incontinences per day calculated as the average daily incontinence
             episode frequency (IEF) over the 3 days preceding the baseline visit

        Exclusion Criteria:

          -  Significant Baseline renal and/or urinary tract pathology

          -  Previous treatment with any endovesical pharmacology agent including detrusor
             Botulinum Toxin injection
Clinical trial NCT00186277 (phase 2, status: completed)
Conditions: bladder cancer
ICD codes: D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, D41.4
Drugs: oxaliplatin, taxotere
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        -  Patient Population Type: Advanced Muscle Invasive Bladder Cancer

          -  Prior Therapy: One prior therapy for advanced disease

          -  Disease: Measurable disease

          -  ECOG Performance: 0,1

          -  Indication: Histologically Proven Carcinoma of the bladder

          -  For female patient of childbearing potential, neither pregnant nor breastfeeding, and
             under active contraception

          -  Allergies: No known allergy to one of the study drugs

          -  Patient Status:

          -  No CNS metastases

          -  No peripheral neuropathy > grade1

          -  No other serious concomitant illness

          -  Fully recovered from any prior therapy

          -  Informed Consent: Patient and doctor have signed informed consent

          -  Lower Age Limit: Lower age limit >18

          -  Upper Age Limit: Upper Age Limit <70

          -  ANC: ANC >1500/mm3 or WBC > 3000/mm3

          -  Platelets: Platelets >100,000/mm3

          -  Creatinine: Creatinine <1.8mg/dL

          -  Bilirubin: Bilirubin <=2.0 x ULN

          -  SGPT: SGPT (ALT) <=1.5 x ULN (<4xULN if liver metastases present)

          -  RBC: Hemoglobin > 9.0g/dL

          -  Cardiovascular: No active congestive heart failure, no uncontrolled angina, no
             myocardial infarction within the past 6 months

          -  Patients with metastatic cancer of the urothelial tract (TCC, Adenocarcinoma)

          -  No prior exposure to Oxaliplatin

          -  No cytotoxics or radiation 4 weeks prior to enrolling on protocol

          -  PT/PTT normal
Clinical trial NCT02015520 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: clazakizumab, placebo (matching with clazakizumab)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Diagnosis of active Rheumatoid Arthritis (RA) by standard criteria (American
             Rheumatism association (ARA) [1987] or American College of Rheumatology/European
             League Against Rheumatism (ACR/EULAR) [2010]) at least 16 weeks prior to screening

          -  ACR global functional status class of 1 to 3

          -  Documented evidence of inadequate response tumor necrosis factor (TNF) inhibitors

          -  All subjects must have been receiving treatment with a minimum dose of 15 mg per week
             of Methotrexate for at least 12 weeks and at a stable dose for 28 days prior to
             screening. A dose as low as 10 mg Methotrexate is permitted if 15 mg could not be
             reached, due to toxicity. In Japan, Korea and Taiwan, a minimum dose of 7.5 mg per
             week is permitted. Additional treatment with Hydroxychloroquine or Chloroquine is
             permitted, if it is at a dose approved for the treatment of RA and the dose has been
             stable for at least 28 days prior to screening

          -  Minimum of 6 swollen and 6 tender joints on a 66/68 joint count at screening and at
             baseline (Day 1)

          -  Elevated High-sensitivity (hs) CRP and/or ESR

        Exclusion Criteria:

          -  Active serious infection

          -  History of or active tuberculosis (TB)

          -  Elevated liver function tests (LFTs)
Clinical trial NCT00320450 (phase 2, status: completed)
Conditions: arthritis, rheumatoid
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: sb-681323
SMILES: [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Females cannot be pregnant or lactating.

          -  Must use defined contraceptive methods if of child-bearing potential.

          -  BMI range: 18.5-35.0 kg/m2.

          -  Diagnosis of RA (rheumatoid arthritis) according to revised 1987 American College of
             Rheumatology (ACR) criteria.

          -  If other RA-medication is used: Disease-Modifying Anti-Rheumatic Drug (DMARDS) must be
             stable for at least 8 weeks before first trial visit.

          -  If other oral anti-RA therapies are used, these must have been stable at least 4 weeks
             before first trial visit.

          -  If Methotrexate medication is used as RA-therapy, Folate supplement must be taken with
             stable red cell folate levels.

          -  Must give informed consent.

          -  Must abstain from alcohol during the trial participation.

        Exclusion Criteria:

          -  Non-responder on biological RA treatment.

          -  Has a positive alcohol screen.

          -  Any history of liver disease.

          -  Positive Hepatitis B surface antigen or Hepatitis C antibody result within 3 months of
             screening.

          -  Have any significant disease that places the subject at unacceptable risk as a
             participant in this trial.

          -  Acute infection.

          -  History of active tuberculosis.

          -  History of repeated or chronic infection.

          -  History of malignancy.

          -  History of HIV or other immunosuppressive diseases.

          -  Participated in a clinical trial within the last 3 months for non-biological therapies
             and 6 months for biological therapies.

          -  Uncontrolled diabetes or psoriasis.
Clinical trial NCT01640080 (phase 2, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: esketamine, esketamine, placebo
SMILES: CNC1(CCCCC1=O)C1=CC=CC=C1Cl, CNC1(CCCCC1=O)C1=CC=CC=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Be medically stable on the basis of clinical laboratory tests

          -  Diagnostic for major depressive disorder (MDD) without psychotic features

          -  Have an inadequate response to at least 1 antidepressant in the current episode of
             depression and at least one other inadequate treatment response to an antidepressant
             either in the current episode or in a previous episode

          -  Women must be not pregnant; women must be postmenopausal, surgically sterile or, if
             heterosexually active, practicing a highly effective method of birth control during
             the study and for 3 months after receiving the last dose of study drug

          -  Men must agree to use a double barrier method of birth control and to not donate sperm
             during the study and for 3 months after receiving the last dose of study drug

          -  Signed informed consent document

        Exclusion Criteria:

          -  History of, or current signs and symptoms of diseases or conditions that would make
             participation not be in the best interest (eg, compromise the well-being) of the
             patient or that could prevent, limit, or confound the protocol-specified assessments

          -  Has uncontrolled hypertension (systolic blood pressure (SBP)> 160 mmHg or diastolic
             blood pressure (DBP)> 90 mmHg despite diet, exercise or a stable dose of an allowed
             anti-hypertensive treatment) or any past history of hypertensive crisis

          -  Has known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection,
             or have positive results at screening

          -  Has a primary diagnosis of current (active) generalized anxiety disorder, panic
             disorder, obsessive compulsive disorder, posttraumatic stress disorder, anorexia
             nervosa, or bulimia nervosa

          -  Has a history or current diagnosis of a psychotic disorder, bipolar disorder, mental
             retardation, or borderline personality disorders, mood disorder with postpartum onset,
             somatoform disorders or chronic fatigue syndrome

          -  Has had major surgery, (eg, requiring general or local anesthesia) within 4 weeks
             before screening, or will not have fully recovered from surgery, or planned surgery
             during the time the subject is expected to participate in the study
Clinical trial NCT00069927 (phase 2, status: terminated)
Conditions: depression, neurotoxicity, unspecified childhood solid tumor, protocol specific
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32, G92.00, G92.01, G92.02, G92.03, G92.04, G92.05, H01.009, H02.209, H02.009, H02.109, H04.209, H05.409, H10.509
Drugs: adderall-xr®, concerta®
SMILES: COC(=O)C(C1CCCCN1)C1=CC=CC=C1
Reason stopped: 
    only 12 subjects enrolled. dsmb recommended closing due to lack of feasibility
  
Eligibility criteria:

        INCLUSION CRITERIA:

          -  Between the ages of 6-17 at the time of study participation.

          -  Have a diagnosis of any malignancy that required CNS treatment such as surgery and/or
             irradiation and/or intrathecal chemotherapy. (Patients treated with systemic
             chemotherapy alone are not eligible to participate)

          -  Off treatment and cancer free for a minimum of 6 months.

          -  Have a proficiency in English.

        EXCLUSION CRITERIA:

          -  Patients with an estimated intelligence quotient (IQ) of less than 65 (based on the
             Wide Range Achievement Test (WRAT-3) Reading subtest) are not eligible to continue on
             study.

          -  At least one standard deviation below the level of performance predicted by their IQ
             on at least 2 of the 3 WISC-III subtests.

          -  Diagnosed with Attention Deficit Disorder (ADD) or Attention Deficit Hyperactivity
             Disorder (ADHD) prior to their cancer diagnosis.

          -  Currently taking antidepressants, antipsychotics, or other stimulants.

          -  Are blind.

          -  Have glaucoma.

          -  Family history of motor and phonic tics or Tourette's syndrome.

          -  Have seizures not controlled by antiepileptic drugs. (Note: Patients who are not
             experiencing seizure activity, having been on a stable dose of an antiepileptic drug
             for at least 12 weeks may participate)

          -  Taking a monoamine oxidase (MAO) inhibitor.

          -  Have a history of cardiovascular disease, uncontrolled hypertension or
             hyperthyroidism.
Clinical trial NCT00512083 (phase 2, status: completed)
Conditions: leukemia, myeloid
ICD codes: C92.Z1, C92.Z2, C92.91, C92.92, C92.Z0, C92.90, C92.11
Drugs: as1411
SMILES: [H][C@]1(O)C[C@@]([H])(O[C@]1([H])COP(O)(=O)O[C@@]1([H])C[C@@]([H])(O[C@]1([H])COP(O)(=O)O[C@@]1([H])C[C@@]([H])(O[C@]1([H])COP(O)(=O)O[C@@]1([H])C[C@@]([H])(O[C@]1([H])COP(O)(=O)O[C@@]1([H])C[C@@]([H])(O[C@]1([H])COP(O)(=O)O[C@@]1([H])C[C@@]([H])(O[C@]1([H])COP(O)(=O)O[C@@]1([H])C[C@@]([H])(O[C@]1([H])COP(O)(=O)O[C@@]1([H])C[C@@]([H])(O[C@]1([H])COP(O)(=O)O[C@@]1([H])C[C@@]([H])(O[C@]1([H])COP(O)(=O)O[C@@]1([H])C[C@@]([H])(O[C@]1([H])COP(O)(=O)O[C@@]1([H])C[C@@]([H])(O[C@]1([H])COP(O)(=O)O[C@@]1([H])C[C@@]([H])(O[C@]1([H])COP(O)(=O)O[C@@]1([H])C[C@@]([H])(O[C@]1([H])COP(O)(=O)O[C@@]1([H])C[C@@]([H])(O[C@]1([H])COP(O)(=O)O[C@@]1([H])C[C@@]([H])(O[C@]1([H])COP(O)(=O)O[C@@]1([H])C[C@@]([H])(O[C@]1([H])COP(O)(=O)O[C@@]1([H])C[C@@]([H])(O[C@]1([H])COP(O)(=O)O[C@@]1([H])C[C@@]([H])(O[C@]1([H])COP(O)(=O)O[C@@]1([H])C[C@@]([H])(O[C@]1([H])COP(O)(=O)O[C@@]1([H])C[C@@]([H])(O[C@]1([H])COP(O)(=O)O[C@@]1([H])C[C@@]([H])(O[C@]1([H])COP(O)(=O)O[C@@]1([H])C[C@@]([H])(O[C@]1([H])COP(O)(=O)O[C@@]1([H])C[C@@]([H])(O[C@]1([H])COP(O)(=O)O[C@@]1([H])C[C@@]([H])(O[C@]1([H])COP(O)(=O)O[C@@]1([H])C[C@@]([H])(O[C@]1([H])COP(O)(=O)OC1([H])CC([H])(OC1([H])CO)N1C=NC2=C1NC(=N)N=C2O)N1C=NC2=C1NC(=N)N=C2O)N1C=C(C)C(O)=NC1=O)N1C=NC2=C1NC(=N)N=C2O)N1C=NC2=C1NC(=N)N=C2O)N1C=C(C)C(O)=NC1=O)N1C=NC2=C1NC(=N)N=C2O)N1C=NC2=C1NC(=N)N=C2O)N1C=C(C)C(O)=NC1=O)N1C=NC2=C1NC(=N)N=C2O)N1C=NC2=C1NC(=N)N=C2O)N1C=C(C)C(O)=NC1=O)N1C=C(C)C(O)=NC1=O)N1C=NC2=C1NC(=N)N=C2O)N1C=C(C)C(O)=NC1=O)N1C=NC2=C1NC(=N)N=C2O)N1C=NC2=C1NC(=N)N=C2O)N1C=C(C)C(O)=NC1=O)N1C=NC2=C1NC(=N)N=C2O)N1C=NC2=C1NC(=N)N=C2O)N1C=C(C)C(O)=NC1=O)N1C=NC2=C1NC(=N)N=C2O)N1C=NC2=C1NC(=N)N=C2O)N1C=C(C)C(O)=NC1=O)N1C=NC2=C1NC(=N)N=C2O)N1C=NC2=C1NC(=N)N=C2O
Eligibility criteria:

        Inclusion Criteria:

          -  primary refractory or relapsed AML

          -  confirmed diagnosis of AML (de novo or secondary) as defined by WHO classification
             (Vardiman 2002)

          -  aged at least 18 years

        Exclusion Criteria:

          -  initial diagnosis of acute promyelocytic leukemia as defined by
             French-American-British criteria (Bennett 1976)

          -  patient in blast crisis stage of chronic myeloid leukemia

          -  received high-dose cytarabine (total cumulative dose of >6g/m sq)in last 6 months

          -  interval of <6 months between first onset of last complete remission and current
             relapse

          -  those with primary refractory leukemia who have received more than three previous
             induction cycles

          -  relapsed patients who have received more than three previous treatment regimens